BERLIN (Reuters) -German pharma company Bayer reported positive study results for its anticoagulant asundexian on Sunday, two years after a research setback for the promising blood thinner candidate.
In a Phase III study, a daily dose of 50 milligrams significantly reduced the risk of ischemic stroke compared with a placebo, Bayer said.
Detailed results from the OCEANIC-STROKE study will be presented at an upcoming scientific congress, said Bayer.
Bayer added that it plans to speak with health authorities worldwide in preparation for the submission of marketing authorisation applications.
Bayer had originally predicted that asundexian would have peak sales potential of more than 5 billion euros ($5.76 billion) - more than any of its other drugs.
At the end of 2023, the company had a major setback with the drug after it failed in a pivotal clinical trial involving patients with atrial fibrillation and a risk of stroke.
($1 = 0.8687 euros)
(Reporting by Joern Poltz. Writing by Miranda Murray. Editing by Jane Merriman)
Tatiana Schlossberg, JFK's granddaughter, dies at 35 after terminal cancer diagnosis- 'No Kings' protests recap: More than 8 million turned out across all 50 states, organizers say
- NASA releases stunning new images captured by the Artemis II moon mission, including 'Earthset' and a solar eclipse from space
- I'm 18 and founded an AI startup. I have to wake up at 3 a.m. to work on it before school, but it's worth every sleepless night.
- Italian authorities detain civilian rescue ship, German NGO says
- An ex-FBI agent analyzes what we learned from Savannah Guthrie's 'Today' show interview amid the search for her mother Nancy
- Moderna to complete US mRNA manufacturing network with $140 million investment
- Figure out how to Perceive Warnings while Looking for an Auto Collision Lawyer
- 'Here we go again': Businesses grapple with fuel costs
